Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALKS – Alkermes plc

Alkermes plc
ALKS
$29.75
Name : Alkermes plc
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $4,911,070,720.00
EPSttm : 2.07
finviz dynamic chart for ALKS
Alkermes plc
$29.75
2.37%
$0.69

Float Short %

8.6

Margin Of Safety %

-10

Put/Call OI Ratio

0.56

EPS Next Q Diff

-0.1

EPS Last/This Y

-0.49

EPS This/Next Y

-0.2

Price

29.76

Target Price

41.5

Analyst Recom

1.69

Performance Q

-1

Relative Volume

0.77

Beta

0.52

Ticker: ALKS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ALKS26.120.716.5224041
2025-07-28ALKS26.170.700.7124096
2025-07-29ALKS270.690.1024395
2025-07-30ALKS27.930.650.8424366
2025-07-31ALKS26.480.670.6324888
2025-08-01ALKS26.550.670.2324908
2025-08-04ALKS26.630.660.5425024
2025-08-05ALKS26.580.650.1825096
2025-08-06ALKS26.560.640.9125643
2025-08-07ALKS26.590.640.7525759
2025-08-08ALKS26.70.640.1725850
2025-08-11ALKS26.550.640.0325996
2025-08-12ALKS27.420.630.2526192
2025-08-13ALKS28.640.610.1927337
2025-08-14ALKS28.260.610.2627322
2025-08-15ALKS29.060.600.3027952
2025-08-18ALKS28.110.471.4415206
2025-08-19ALKS28.850.500.3015719
2025-08-20ALKS28.980.503.0915817
2025-08-21ALKS29.070.555.6316544
2025-08-22ALKS29.760.560.2416718
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ALKS26.13-46.1-139.11.70
2025-07-28ALKS26.10-46.1-133.81.70
2025-07-29ALKS27.00-46.1-121.11.70
2025-07-30ALKS27.93-46.1-108.61.70
2025-07-31ALKS26.49-47.1-135.41.72
2025-08-01ALKS26.55-47.1-104.11.72
2025-08-04ALKS26.64-47.1-103.91.72
2025-08-05ALKS26.60-47.1-105.71.72
2025-08-06ALKS26.56-47.1-105.71.73
2025-08-07ALKS26.59-47.1-104.51.73
2025-08-08ALKS26.71-47.1-103.51.73
2025-08-11ALKS26.55-47.1-107.61.73
2025-08-12ALKS27.43-47.1-91.61.73
2025-08-13ALKS28.63-47.1-87.71.73
2025-08-14ALKS28.26-47.1-110.21.73
2025-08-15ALKS29.06-47.1-94.01.73
2025-08-18ALKS28.11-47.1-117.91.73
2025-08-19ALKS28.85-47.1-94.81.73
2025-08-20ALKS28.98-47.1-103.41.73
2025-08-21ALKS29.07-47.1-103.81.73
2025-08-22ALKS29.76-47.1-95.61.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ALKS-11.072.867.80
2025-07-28ALKS-11.072.787.80
2025-07-29ALKS-11.072.787.80
2025-07-30ALKS-11.072.787.80
2025-07-31ALKS-11.072.787.80
2025-08-01ALKS-8.872.787.79
2025-08-04ALKS-8.872.297.79
2025-08-05ALKS-8.872.297.79
2025-08-06ALKS-8.872.297.79
2025-08-07ALKS-8.872.297.79
2025-08-08ALKS-8.872.297.79
2025-08-11ALKS-8.872.367.79
2025-08-12ALKS-8.872.368.56
2025-08-13ALKS-8.872.368.56
2025-08-14ALKS-8.872.368.56
2025-08-15ALKS-0.372.368.56
2025-08-18ALKS-0.37-1.518.60
2025-08-19ALKS-0.31-1.518.60
2025-08-20ALKS-0.31-1.518.60
2025-08-21ALKS-0.28-1.518.60
2025-08-22ALKS-0.28-1.518.60
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.39

Avg. EPS Est. Next Quarter

0.42

Insider Transactions

-0.28

Institutional Transactions

-1.51

Beta

0.52

Average Sales Estimate Current Quarter

354

Average Sales Estimate Next Quarter

369

Fair Value

26.8

Quality Score

99

Growth Score

40

Sentiment Score

68

Actual DrawDown %

18.3

Max Drawdown 5-Year %

-33.2

Target Price

41.5

P/E

14.28

Forward P/E

18.65

PEG

P/S

3.26

P/B

3.02

P/Free Cash Flow

10.23

EPS

2.08

Average EPS Est. Cur. Y​

1.73

EPS Next Y. (Est.)

1.52

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.15

Relative Volume

0.77

Return on Equity vs Sector %

-3.2

Return on Equity vs Industry %

13.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-95.6
Alkermes plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading